Concinnity Genetics is pioneering advancements in gene therapy safety through the development of innovative RNA-based control systems. These systems are designed to provide precise control over gene therapies, allowing them to respond dynamically to biological signals even after administration. By utilizing synthetic biology and artificial intelligence, Concinnity creates highly modular control mechanisms that can be tailored to various therapeutic applications. This approach enhances the reliability and precision of gene therapies, enabling them to mitigate side effects and improve patient outcomes.

The company's technology is characterized by its compatibility with a wide range of therapies and existing technologies, making it versatile across different medical fields. Concinnity's RNA control systems can be integrated into mRNA therapeutics and AAV delivery vectors, utilizing the 3' UTR region of the gene cassette for improved modularity. Their proprietary AI platform facilitates rapid development and optimization of these control systems, allowing for a scalable and efficient design process. This innovative framework not only enhances the safety profile of gene therapies but also broadens their applicability, potentially transforming treatment options for a variety of diseases.

United Kingdom

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Concinnity Genetics

Company Details